Zephyr AI是一家专注于开发快速且可解释的人工智能解决方案以实现精准医疗的医疗技术公司。近日，该公司宣布成功完成了1.11亿美元的A轮融资，由Revolution Growth、礼来公司、Jeff Skoll和EPIQ Capital Group等投资方共同参与。
精准医疗是当前医疗领域的一个热门话题，它通过结合病人的基因信息和临床数据，为患者提供个性化的治疗方案。Zephyr AI的使命是通过人工智能技术，加速这一过程，并提高治疗效果。
此次融资的成功，不仅体现了投资者对Zephyr AI技术和团队的认可，也显示了精准医疗市场的巨大潜力。随着资金的注入，Zephyr AI将能够进一步优化其算法，加快产品开发，并扩展其服务范围。
Zephyr AI的联合创始人兼首席执行官表示：“这笔融资将帮助我们加速推进精准医疗的实现，我们相信，通过人工智能技术，我们可以为患者提供更好的医疗服务，为医疗行业带来革命性的变化。”
随着精准医疗的不断发展，Zephyr AI有望成为这一领域的领军企业，为全球的患者带来福音。
英文标题：Zephyr AI, a Precision Medicine AI Startup, Raises $111 Million in Series A Funding
英文关键词：Precision Medicine, AI, Funding
英文新闻内容：
Zephyr AI, a medical technology company dedicated to developing fast and explainable artificial intelligence solutions for precision medicine, has announced the completion of a $111 million Series A funding round, led by Revolution Growth, Eli Lilly and Company, Jeff Skoll, and EPIQ Capital Group, among other investors.
Precision medicine, a hot topic in the medical field, aims to provide personalized treatment plans by combining patients’ genetic information with clinical data. Zephyr AI’s mission is to accelerate this process and enhance treatment outcomes through AI technology.
The successful funding round not only demonstrates the investors’ recognition of Zephyr AI’s technology and team but also highlights the potential of the precision medicine market. With the injection of capital, Zephyr AI will be able to further optimize its algorithms, expedite product development, and expand its service offerings.
“This funding will help us accelerate the realization of precision medicine,” said Zephyr AI’s co-founder and CEO. “We believe that through AI technology, we can provide better medical services to patients and bring revolutionary changes to the medical industry.”
As precision medicine continues to evolve, Zephyr AI is poised to become a leader in this field, bringing hope to patients around the globe.
【来源】https://www.businesswire.com/news/home/20240312475536/en/Zephyr-AI-Raises-111-Million-in-Series-A-Financing
Views: 1